Patient info Open main menu

Enzoderm 5% gel – Summary of Product Characteristics (SmPC) for healthcare professionals

Last updated: · Text from the MHRA, as of · About this document

Medicine status: No longer supplied Details

The Summary of Product Characteristics (SmPC) is written for healthcare professionals. Patients will find plain advice in the patient information leaflet.

Medicine strength:
5% (50 mg/gram)
Still supplied:
The same active substance, strength and form in the NHS Dictionary of Medicines and Devices (dm+d). Ask your pharmacist or doctor before changing to another make.
Other strengths and forms:
Contains active substance:
Similar medicines:

Summary of Product Characteristics (SmPC) - Enzoderm 5% gel

1 NAME OF THE MEDICINAL PRODUCT

Benzoyl Peroxide 5% Gel

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Benzoyl Peroxide 5%.

3 PHARMACEUTICAL FORM

Gel

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

All stages of acne vulgaris.

4.2 Posology and method of administration

Adults

Treatment should be initiated with Benzoyl Peroxide 5% Gel once daily. The affected areas should be washed with soap and water and then dried before Benzoyl Peroxide 5% Gel is applied. For stubborn cases treatment may be continued with Benzoyl Peroxide 10% Gel provided that Benzoyl Peroxide 5% Gel has been well tolerated. For particularly sensitive skin, Benzoyl Peroxide 5% Gel should be applied on alternate days.

Children

Not applicable.

The Elderly

Not applicable.

4.3 Contraindications

Known hypersensitivity to benzoyl peroxide.

4.4 Special warnings and precautions for use

Avoid contact with eyes and mucosae. If the skin is exposed to strong or prolonged sunlight, this medicine should be applied at longer intervals and a highly protective sun-screening agent should be used. This medicine should only be applied to dry skin to avoid unnecessary irritation.

For external use only. Care should be taken to avoid contact with dyed fabrics as this product may adversely affect dye fastness.

4.5 Interaction with other medicinal products and other forms of interaction

This is an oxidising agent, therefore it should not be used at the same time as other topical agents, which would react with an oxidising agent.

4.6 Fertility, Pregnancy and lactation

The normal use of this medicine is not contraindicated during pregnancy.

4.7 Effects on ability to drive and use machines

Not applicable.

4.8 Undesirable effects

As with all keratolytic substances itching reddening burning and a feeling of skin tension may occur. This may be relieved by the use of a moisturising cream

or by temporary interruption of the use.

In rare cases a contact dermatitis occur in which event treatment should be stopped immediately.

Face Oedema.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard

4.9 Overdose

Not applicable.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Benzoyl peroxide has a strong antibacterial action against propioni-bacterium acnes. It is has keratolytic and sebostatic, which cause some dryness and desquamation.

5.2 Pharmacokinetic properties

None stated.

5.3 Preclinical safety data

None stated.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Carbomer 980, Polyoxyethylene 23 Lauryl Ether, Propylene Glycol, Sodium Hydroxide and Purified water

6.2 Incompatibilities

This is an oxydising agent, therefore it should not be used at the same time as other topical agents, which would react with an oxidising agent.

6.3 Shelf life

24 months

6.4 Special precautions for storage

Store below 25’C

6.5 Nature and contents of container

Low density polyethylene tubes 30g

Low density polyethylene tubes 40g

6.6 Special precautions for disposal

No Data Held

7 MARKETING AUTHORISATION HOLDER

Diomed Developments Limited (trading as Dermal Laboratories)

Tatmore Place, Gosmore

Hitchin, Herts

SG4 7QR

8 MARKETING AUTHORISATION NUMBER(S)

PL 00173/0411

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

10 DATE OF REVISION OF THE TEXT

27/08/2022

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 00173/0411

Last revision stated in the text: 27 August 2022 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Enzoderm 5% gel

Active substance Benzoyl peroxide
Strength 5% (50 mg/gram)
Pharmaceutical form Cutaneous gel
How is it taken Cutaneous
Excipients Carbomer 980, Polyoxyethylene 23 Lauryl Ether, Propylene Glycol, Sodium Hydroxide and Purified water
Is it available? No, all its packs are listed as discontinued (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 24 months
Storage Store below 25°C
Drug group (ATC)
  1. D Dermatologicals
    1. D10 Anti-acne preparations
      1. D10A Anti-acne preparations for topical use
        1. D10AE Peroxide anti-acne preparations for topical use
          1. D10AE01 benzoyl peroxide
Marketing authorisation PL 00173/0411
Marketing authorisation holder Diomed Developments Limited (trading as Dermal Laboratories)
Codes BNF 13060100

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.